scholarly journals Rituximab in refractory myasthenia gravis: a prospective, open‐label study with long‐term follow‐up

2016 ◽  
Vol 3 (7) ◽  
pp. 552-555 ◽  
Author(s):  
Dustin Anderson ◽  
Cecile Phan ◽  
Wendy S. Johnston ◽  
Zaeem A. Siddiqi
Keyword(s):  
Myasthenia Gravis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of DYT1 dystonia patients treated by deep brain stimulation: An open-label study

2010 ◽  
Vol 25 (3) ◽  
pp. 289-299 ◽  
Author(s):  
Laura Cif ◽  
Xavier Vasques ◽  
Victoria Gonzalez ◽  
Patrice Ravel ◽  
Brigitte Biolsi ◽  
...  
Keyword(s):  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Dyt1 Dystonia ◽  
Long Term Follow Up ◽  
Deep Brain

scholarly journals Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

Trials ◽  
2014 ◽  
Vol 15 (1) ◽  
Author(s):  
Paul Gillard ◽  
Didier Giet ◽  
Stéphane Heijmans ◽  
Mamadou Dramé ◽  
Karl Walravens ◽  
...  
Keyword(s):  
Immune Response ◽  
Elderly Persons ◽  
Open Label ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Open Label Study ◽  
Label Study ◽  
Cellular Immune

scholarly journals Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study

2018 ◽  
Vol 10 (9) ◽  
pp. 679-687 ◽  
Author(s):  
Daisuke Ito ◽  
Kazuyuki Inoue ◽  
Takashi Sumita ◽  
Keiko Hamaguchi ◽  
Kimie Kaneko ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Long Term Effects ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study

2005 ◽  
Vol 107 (3) ◽  
pp. 187-190 ◽  
Author(s):  
José M. Ponseti ◽  
Jamal Azem ◽  
José M. Fort ◽  
Agustín Codina ◽  
J. Bruno Montoro ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
One Year

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study

2014 ◽  
Vol 121 (1) ◽  
pp. 114-122 ◽  
Author(s):  
Victoria Gonzalez ◽  
Laura Cif ◽  
Brigitte Biolsi ◽  
Sara Garcia-Ptacek ◽  
Anne Seychelles ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Deep Brain

Object To date, experience of globus pallidus internus (GPi) deep brain stimulation (DBS) in the treatment of Huntington's disease (HD) has been limited to a small number of case reports. The aim of this study was to analyze long-term motor outcome of a cohort of HD patients treated with GPi DBS. Methods Seven patients with pharmacologically resistant chorea and functional impairment were included in a prospective open-label study from 2008 to 2011. The main outcome measure was the motor section of the Unified Huntington's Disease Rating Scale. The primary end point was reduction of chorea. Results Patients underwent MRI-guided bilateral GPi implantation. The median duration of follow-up was 3 years. A significant reduction of chorea was observed in all patients, with sustained therapeutic effect; the mean improvement on the chorea subscore was 58.34% at the 12-month follow-up visit (p = 0.018) and 59.8% at the 3-year visit (p = 0.040). Bradykinesia and dystonia showed a nonsignificant trend toward progressive worsening related to disease evolution and partly to DBS. The frequency of stimulation was 130 Hz for all patients. DBS-induced bradykinesia was managed by pulse-width reduction or bipolar settings. Levodopa mildly improved bradykinesia in 4 patients. Regular off-stimulation tests confirmed a persistent therapeutic effect of DBS on chorea. Conclusions GPi DBS may provide sustained chorea improvement in selected HD patients with pharmacologically resistant chorea, with transient benefit in physical aspects of quality of life before progression of behavioral and cognitive disorders. DBS therapy did not improve dystonia or bradykinesia. Further studies including quality of life measures are needed to evaluate the impact of DBS in the long-term outcome of HD.

Sign in / Sign up

Export Citation Format

Share Document